AstraZeneca says US trial data shows vaccine is 79 per cent effective, finds no blood clot concerns

AstraZeneca’s Covid-19 vaccine provided strong protection against disease and complete protection against hospitalisation and death across all age groups in a late-stage US study, the company announced Monday.AstraZeneca said its experts had also identified no safety concerns related to the vaccine, including a rare blood clot that was identified in Europe. Scientists found no increased risk of clots among the more than 20,000 people who got at least one dose of the AstraZeneca shot. Although…

Read the original article at South China Morning Post